M&A Deal Summary

NeoGenomics Acquires Trapelo Health

On March 24, 2021, NeoGenomics acquired information services company Trapelo Health for 65M USD

Acquisition Highlights
  • This is NeoGenomics’ 1st transaction in the Information Services sector.
  • This is NeoGenomics’ 4th largest (disclosed) transaction.
  • This is NeoGenomics’ 4th transaction in the United States.
  • This is NeoGenomics’ 1st transaction in Michigan.

M&A Deal Summary
Date 2021-03-24
Target Trapelo Health
Sector Information Services
Buyer(s) NeoGenomics
Deal Type Add-on Acquisition
Deal Value 65M USD

Target

Trapelo Health

Grand Rapids, Michigan, United States
Trapelo Health is a health information services company helping community oncologists incorporate molecular oncology into their practice. Trapelo Health was founded in 2009 and is based in Grand Rapids, Michigan.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

NeoGenomics

Fort Myers, Florida, United States
Category Company
Founded 2001
Sector Life Science
Employees2,100
Revenue 592M USD (2023)
DESCRIPTION

NeoGenomics is a clinical laboratory that specializes in cancer genetics diagnostic testing. The company’s testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology and molecular genetic testing. NeoGenomics was founded in 2001 and is based in Fort Myers, Florida.

DEAL STATS #
Overall 4 of 6
Sector (Information Services) 1 of 1
Type (Add-on Acquisition) 3 of 5
State (Michigan) 1 of 1
Country (United States) 4 of 4
Year (2021) 1 of 3
Size (of disclosed) 4 of 5
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2018-10-23 Genoptix

Carlsbad, California, United States

Genoptix, Inc. is one of the largest hematopathology testing laboratories in the U.S., providing thousands of oncologists and pathologists across the United States with comprehensive testing solutions in hematology and solid tumor molecular profiling. Genoptix, Inc. was founded in 1999 and is based in Carlsbad, California.

Buy $126M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-05-05 Inivata

Cambridge, United Kingdom

Inivata is a liquid biopsy company with its InVision platform that unlocks essential genomic information from a simple blood draw to guide and personalize cancer treatment, monitor response, and detect relapse. Inivata's technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge. Its lead product, InVisionFirst-Lung is commercially available internationally and through NeoGenomics in the US. It offers competitive sensitivity and turnaround, providing molecular insights that enable clinicians to make more informed treatment decisions for advanced NSCLC patients. Inivata has also launched the personalized RaDaR assay - allowing the highly sensitive detection of residual disease and recurrence - which has been granted Breakthrough Device Designation by the US FDA.

Buy $390M
Mergr

Product

Company

Legal